Molecular markers in acute myeloid leukaemia
- First Online:
- Cite this article as:
- Kühnl, A. & Grimwade, D. Int J Hematol (2012) 96: 153. doi:10.1007/s12185-012-1123-9
- 2k Views
An increasing number of cytogenetic and molecular genetic aberrations have been identified in acute myeloid leukaemia (AML), highlighting the biological heterogeneity of the disease. Moreover, the characterisation of specific molecular abnormalities provides the basis for targeted therapies, such as all trans retinoic acid (ATRA) and arsenic trioxide treatment in acute promyelocytic leukaemia or tyrosine kinase inhibitors in AML with FLT3 mutations. Several cytogenetic and molecular genetic changes have been shown to be prognostically relevant and have been acknowledged in the latest WHO classification of AML as separate entities. A detailed marker assessment at diagnosis is crucial for risk-stratification of AML patients, allowing the identification of those at high risk of relapse, who may benefit from early allogeneic stem cell transplantation. Finally, molecular markers are important for the detection of minimal residual disease after initial therapy and during long-term follow-up, which enables a more tailored treatment approach for individual AML patients.
KeywordsAMLCytogeneticsMolecular geneticsMinimal residual disease
Pre-treatment prognostic factors
Revised MRC AML cytogenetic classification applied in younger adults 
Entities not classified as favourable or adverse
In the absence of favourable risk cytogenetic abnormalities:
abn(3q) [excluding t(3;5)(q21–25;q31–35)], inv(3)(q21q26)/t(3;3)(q21;q26)
t(11q23) [excluding t(9;11)(p21–22;q23) and t(11;19)(q23;p13)]
Complex karyotype (≥4 unrelated abnormalities)
The favourable risk group includes 3 balanced translocations/inversions: t(15;17)(q22;q21)/PML-RARA in acute promyelocytic leukaemia (APL), as well as the core binding factor (CBF) leukaemias with t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. Patients in this group usually show a complete remission (CR) rate above 90 %, with an overall survival (OS) of 55–85 % and therefore allogeneic stem cell transplantation (SCT) in first CR is generally not recommended for these patients [4, 5].
Additional cytogenetic abnormalities do not predict for poorer outcome in AML with favourable risk cytogenetics. Indeed in CBF leukaemia with inv(16)/t(16;16), presence of additional abnormalities, particularly trisomy 22, is associated with a better outcome (reviewed in ).
Patients in the adverse risk group have a CR rate of only 60 % and a dismal OS of about 10–20 % [2, 6]. For these patients an allograft in first CR or experimental treatment strategies should be considered. The karyotypes −5/del(5q), −7, abn(3q), translocations involving the MLL locus at 11q23, and complex karyotypes are consistently included into the adverse risk categories of different AML study groups (reviewed in ).
MLL rearrangements have been generally considered to predict a poor outcome; however, different studies indicate that the prognostic impact of MLL translocations depends on the respective fusion partner. The t(6;11)(q27;q23) and t(10;11)(p12;q23), involving the AF6 and AF10 genes, respectively, were shown to confer inferior prognosis [2, 7, 8]. In contrast, the t(9;11)(p21–22;q23) involving MLLT3 and t(11;19)(q23;p13) in which the fusion partner is the ELL or ENL gene depending the breakpoint on 19p are associated with a better outcome [2, 9].
Complex karyotypes are associated with deletions of 5q, 7q and 17p (and TP53 mutations), as well as gains of 8q, 11q, and 21q [10, 11]. While various definitions have been used to categorise complex karyotypes, a recent large MRC study which investigated the impact of complexity in AML with intermediate risk aberrations suggested that 4 or more abnormalities provide the most robust and prognostically relevant cut-off . A very recent study involving 824 cases conducted by the Munich Leukemia Laboratory lends further support to standardise the definition of complex karyotype based on the presence of at least 4 unrelated cytogenetic abnormalities .
Besides the refinement of known adverse factors, also new cytogenetic risk entities have been proposed. In a study including almost 2000 younger adults with AML, a monosomal karyotype (defined as the presence of an autosomal monosomy with at least one other autosomal monosomy or structural chromosomal abnormality; excluding CBF AML) has been associated with a particularly unfavourable prognosis and suggested to be more predictive for adverse outcome than a complex karyotype . The adverse prognostic significance of a monosomal karyotype has been confirmed by other studies [2, 12, 14]. However, the vast majority of patients with a monosomal karyotype had already been defined as high risk by the revised MRC cytogenetic classification and the criterion “monosomal karyotype” alone did not reliably classify patients as high risk [2, 12].
As cytogenetic classification in AML becomes more and more complex, large prospective studies are needed to evaluate the clinical utility of known risk categories and potential new risk factors. In particular, the prognostic impact of cytogenetic aberrations of low frequency, like t(v;11)(v;q23) other than t(9;11), del(7q), del(9q), or del(20q) need to be determined. Moreover, the prognostic relevance of additional genetic abnormalities in patients with balanced translocations and other chromosomal abnormalities remains unclear and requires further evaluation.
In recent years, a magnitude of molecular prognostic factors has been identified in AML. This is particularly important for cytogenetically normal (CN)-AML patients and has substantially improved characterisation and risk-stratification of this large, heterogeneous subgroup. To date, more than 90 % of AML patients can be categorised on the basis of either cytogenetic or molecular genetic characteristics.
Thus far, 3 molecular markers [mutations in the genes encoding nucleophosmin (NPM1), Fms-like Tyrosine kinase 3 (FLT3), and CCAAT Enhancer Binding Protein alpha (C/EBPα)] have been consistently demonstrated to be of independent prognostic significance in CN-AML patients and have been widely incorporated into trial risk assignments as well as in daily clinical practice. In addition, a number of studies suggest that detection of mutations in the RUNX1 gene, partial tandem duplication of MLL (MLL-PTD), and overexpression of EVI1 confer independent adverse prognostic information and could serve to further refine risk-stratification (reviewed in ). The prognostic relevance of other more recently identified molecular markers, such as mutations in TET2 [16–18], IDH1/2 [19–25], DNMT3A [26–32], WT1 [33–35], KIT [36–39], ASXL1 [40–44], BCOR , BCORL1 , PHF6 [44, 47], as well as gene expression profiles (reviewed in ), microRNA signatures (reviewed in ), DNA methylation , or aberrant overexpression of single genes like BAALC, ERG, or MN1 (reviewed in ) merits further investigation.
Heterozygous mutations of the NPM1 gene are the most frequent mutations in AML, detected in a third of cases, including approximately half with normal karyotype [51–54]. AML with mutated NPM1 has been acknowledged by the 2008 WHO classification as a provisional separate entity . Mutations of NPM1 are regarded as a primary leukaemic lesion as they are stable throughout the course of the disease and are mutually exclusive with recurrent balanced translocations [56, 57]. They are associated with the presence of FLT3-ITD, IDH1/2, and DNMT3A mutations, but are rarely seen together with mutations of the CEBPA gene [54, 58].
Different NPM1 mutations have been described, all being frameshift mutations by the insertion of 4 (rarely more) bases, in the majority of cases in exon 12 [51, 59]. These mutations lead to an aberrant cytoplasmic localisation of the nucleophosmin protein and impair the protein’s nuclear shuttle function, which is important for activation and stabilisation of tumour suppressors such as p53 and ARF .
Patients with an isolated NPM1 mutation have a more favourable outcome, with higher CR rates, reduced risk of relapse and longer OS [52–54, 61]. However, in most studies this favourable prognosis was only seen in patients with wildtype FLT3. Moreover, the prognostic impact of NPM1 might depend on the presence of additional IDH1/2 mutations . A favourable outcome associated with NPM1 was also observed in elderly AML patients  as well as in relapsed AML cases .
About 20–27 % of AML arising in younger adults and 30–50 % of those with normal karyotype harbour in-frame internal tandem duplications (ITD) of the class III receptor tyrosine kinase FLT3 [64–66]. FLT3 is expressed on normal haematopoietic progenitor cells and is important for cell differentiation, proliferation, and survival . Most FLT3-ITD mutations occur in exons 14 and 15, affecting the juxtamembrane domain which regulates the kinase activity of the receptor . The duplications, which differ in length and insertion sites, lead to constitutive activation of the receptor and promote proliferation of leukaemic cells . CN-AML patients with FLT3-ITD show a significantly inferior outcome compared to patients without the mutation [65, 66, 70, 71]. This is predominantly due to a higher relapse rate in cases with FLT3-ITD, whereas the initial response to chemotherapy is similar. The prognosis is particularly poor for patients with a high FLT3-ITD allelic ratio which may stem from homozygous mutations resulting from acquired uniparental disomy, as well as for patients harbouring the ITD integration site in the beta1-sheet of the tyrosine kinase domain (TKD)-1  and for cases with coexisting mutations of WT1 [34, 73].
The prognostic significance of another, less frequent class of FLT3 mutations involving amino acid substitutions in the TKD (mostly at codons D835 and I836) is still unclear and might depend on the presence of other mutations [74–77]. Both ITD and TKD point mutations of FLT3 are associated with a high white blood cell count and increased LDH levels at diagnosis . FLT3 mutations are more frequent in PML-RARA+ APL and are associated with the clinically aggressive microgranular variant subtype [78–80].
The gene CEBPA is mutated in approximately 5–10 % of AML, mostly CN-AML cases [54, 81]. In addition, germline CEBPA mutations have been reported in familial AML . C/EBPα is a key transcription factor involved in myelopoiesis . Mutations cluster in the amino- and carboxy-terminal regions, with the former leading to expression of a truncated isoform of C/EBPα (p30) and loss of the full length protein (p42) . Carboxy-terminal mutations affect regions involved in mediating dimerisation and DNA-binding. Interestingly, in the majority of patients with CEBPA mutations, both alleles are involved, combining an upstream mutation in one allele with a downstream mutation in the other. Significant insights into the biology of CEBPA mutations have been provided by murine models, which have shown how loss of p42 expression (mimicking biallelic amino-terminal CEBPA mutations) or compound heterozygous mutations affecting amino- and carboxy-terminal regions affect haematopoiesis and give rise to AML . While early studies reported that CEBPA mutation predicts a relatively favourable outcome in AML, it has subsequently been shown that this effect is accounted for by the subset of patients with biallelic mutations, especially those who lack FLT3-ITD [58, 85]. Similar to NPM1, CEBPA-mutated AML has been recognised as a provisional entity in the 2008 WHO classification .
TET2 Mutations of the TET2 gene have been found in various myeloid malignancies and are detected in 10–20 % of AML [17, 18, 88, 89]. TET2 mutations are very heterogeneous and spread throughout the entire coding sequence [17, 18, 88]. They are loss-of-function mutations, in most cases nonsense and frameshift mutations leading to truncated translation. The detection of mutations in both TET2 copies and loss of heterozygosity in different myeloid neoplasms suggest a role of TET2 as a tumour suppressor gene [16, 90, 91]. In vitro and in vivo studies have demonstrated a role for TET2 in myeloid differentiation and self-renewal of stem and progenitor cells [89, 92, 93]; however, the precise mechanisms and downstream effects of TET2 are yet unknown. The TET2 protein is an enzyme catalysing the conversion of 5-methylcytosine to 5-hydroxymethylcytosine which results in demethylation of DNA  and TET2 mutations have been shown to impair this enzymatic function .
The prognostic relevance of TET2 remains controversial—some studies suggest an adverse impact of TET2 mutations on outcome in certain AML subgroups [17, 18]; in other studies no prognostic significance of TET2 was found .
IDH Mutations of the gene encoding the isocitrate dehydrogenase IDH1 in AML were discovered by whole genome sequencing  and are detected in 8–16 % of cases with normal karyotype [19, 21]. Another 12–15 % (which do not harbour an IDH1 mutation) show mutations in IDH2 [20, 96], the mitochondrial homolog of IDH1. Both enzymes convert isocitrate to α-ketoglutarate; however, the mutated proteins exhibit a gain-of-function leading to aberrant accumulation of the oncometabolite 2-hydroxyglutarate (2-HG) [96, 97]. There is a functional overlap between IDH1/2 and TET2 and the two classes of mutations are mutually exclusive [17, 18, 89]. Patients with IDH1/2 and TET2 mutations show a similar epigenetic signature and global DNA hypermethylation . Moreover, it was demonstrated that 2-HG which is generated as a result of mutations in IDH1/2 inhibits TET2 function .
Like for TET2, the impact of IDH mutations on survival of AML patients is not clear yet. Some studies have observed no difference in outcome with respect to the IDH mutation status [20, 21, 25], others have demonstrated a poor prognostic impact in certain AML subgroups [22–24]. Recent studies suggest that the impact of IDH2 on prognosis depends on the mutation site, with the IDH2 R140 mutation being an independent favourable prognostic factor in AML patients [44, 98, 99].
Apart from potential prognostic implications of IDH and TET2, the finding of alterations in enzymatic activities and epigenetic changes in a large proportion of AML patients might lead to the development of new targeted therapies for this patient group.
DNMT3A Mutations of DNMT3A occur in about 14–18 % of AML, including 20–35 % with normal karyotype and are associated with a poorer prognosis [26–32]. DNMT3A mutations are associated with the presence of NPM1, FLT3 and IDH mutations [26, 30]. Several different loss-of-function mutations have been found in all exons of DNMT3A, most frequently a missense point mutation at amino acid R882. DNMT3A is a methyltransferase that converts cytosine to 5-methylcytosine and generates de novo DNA methylation. Aberrant methylation patterns have been implicated in tumourigenesis and tumour progression . The functional consequences of DNMT3A mutations in leukaemia are barely understood. It is suggested that mutations result in a decreased methyltransferase activity of DNMT3A by a dominant-negative mechanism [26, 101]. A recent in vivo study revealed that Dnmt3a-null haematopoietic stem cells have an increased self-renewal capacity and lose their differentiation potential, which was accompanied by hypomethylation of several genes implicated in leukaemogenesis . However, also marked focal hypermethylation was found in the absence of Dnmt3a and it thus remains unclear which biological function of Dnmt3a contributes to the Dnmt3a-null phenotype. Interestingly, knockout of Dnmt3a alone was not sufficient to initiate leukaemia .
Minimal residual disease (MRD) assessment
Response to initial chemotherapy is a strong prognostic factor in AML (reviewed in ). Using cytogenetic analysis including FISH, polymerase chain reaction (PCR) or flow cytometry, the depth of remission and risk of relapse can be determined much more accurately than with conventional cytological methods. With PCR- and flow cytometry-based techniques, the presence of sub-microscopic levels of residual leukaemia can be detected with a sensitivity of up to 1 AML cell in 104–106 bone marrow cells (reviewed in ).
MRD assessment has been applied in 2 different ways: first, at early timepoints to determine the depth of the initial therapy response to better risk-stratify patients and guide postremission therapy; and second, sequential monitoring utilising leukaemia-specific markers to identify an impending relapse, enabling early treatment intervention to prevent progression of the disease.
Real-time quantitative PCR
The method with highest sensitivity for MRD analysis is real-time quantitative PCR (RT-qPCR) for AML-specific target fusion genes or mutations. So far, assays have been successfully performed for PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, MLLT3-MLL, DEK-CAN, and NPM1 mutations (reviewed in ). Given the increasing number of molecular markers identified in AML, at least half of patients harbour a leukaemia-specific target that can potentially be used for PCR-based MRD monitoring. However, not every marker is equally suitable for MRD assessment. For example, the use of FLT3-ITD seems to be limited, since mutational status may differ between leukaemic subclones such that the FLT3-ITD associated with the predominant clone at diagnosis may not be detectable at the time of disease relapse [104–106]. CEBPA mutations are difficult to track due to their heterogeneity and MRD detection of CEBPA has only been performed in one study including 4 patients so far . Another restriction for MRD utility is the background amplification level of markers in the normal bone marrow, which has been a relevant drawback for monitoring of MLL-PTD .
The use of MRD assessment to guide therapy is most advanced in APL, where a standardised RT-qPCR assay has been developed and MRD monitoring is recommended by international treatment guidelines [109, 110]. Longitudinal monitoring of PML-RARA has been shown to be a strong prognostic factor for clinical relapse [110, 111]. Moreover, MRD-guided pre-emptive therapy reduced the rate of overt clinical relapse and was associated with improved survival, particularly in patients with high risk disease [111–113]. In CBF leukaemias, use of RT-qPCR to assess kinetics of disease response predicts subsequent risk of relapse [114–116]. Although, the clinical utility of sequential MRD monitoring in RUNX1-RUNX1T1-associated leukaemias has been questioned due to early reports involving qualitative PCR assays in which fusion transcripts could be detected in patients in long-term remission, subsequent studies using RT-qPCR have shown that relapse of CBF leukaemia is predicted by a rising transcript level.
Several studies have investigated NPM1 mutations as targets for MRD detection using DNA- or RNA-based quantitative PCR assays [117–121]. It has been shown that NPM1-specific monitoring independently predicted the risk of relapse . Moreover, tracking of NPM1 has been successfully applied in the post-transplantation setting and predicted relapse earlier than assessment of chimaerism .
Besides leukaemia-specific mutations or fusion genes, aberrantly overexpressed genes have been considered as potential MRD markers, provided that they are at least 1,000-fold higher expressed than in normal cells and not modulated by regeneration after chemotherapy (reviewed in ). The main focus in this regard has been on WT1, which is overexpressed in about 70 % of AML cases. Early WT1 monitoring has been shown to independently predict the risk of relapse within cytogenetic risk groups; however, high background expression of WT1 in normal haematopoietic cells limits the sensitivity of WT1 assays and makes it inappropriate for long-term follow-up .
For patients who have no suitable molecular MRD marker, monitoring by flow cytometry may be applicable. This technique is based upon the identification of a leukaemia-associated aberrant immunophenotype (LAIP) at diagnosis that is uncommon in normal haematopoietic cells and in regenerating bone marrow. In the majority of cases, LAIPs can be identified in the blast population, which comprise cross-lineage expression of lymphoid antigens, asynchronous antigen expression, and up- or downregulation of antigens (reviewed in ). For MRD detection, either a fixed panel of antibodies or patient-specific antibodies may be used. As the leukaemic immunophenotype frequently changes in AML at relapse, it is recommended to use antibody panels which detect all LAIPs present at diagnosis in order to ensure the stable detection of at least one LAIP during the course of the disease (reviewed in ). These antigen shifts may be caused by the selection of leukaemic subclones during chemotherapy which were not detectable at diagnosis or to a lesser extent by clonal evolution of the blast population. A major problem of using flow cytometry for MRD detection is the large assay variability between different laboratories. Nevertheless, several studies have demonstrated the independent prognostic significance of MRD assessment with flow cytometry after induction and consolidation therapy [124–126]. Thus far, sensitivity of MRD detection using flow cytometry is significantly lower than that of RT-qPCR, which limits the method to early MRD assessment. However, this will be probably overcome with the use of advanced multicolour technologies in the future.
Both for PCR- and flow cytometry-based MRD approaches, large prospective trials are needed to evaluate the clinical utility of MRD in non-APL AML. In this regard, it is particularly important to further standardise the different MRD assays and to equalise time points and cut-offs for MRD detection. Most likely, MRD assessment will provide a useful tool for risk-stratification during therapy and follow-up and may improve outcome for AML patients.
The identification of molecular markers in AML has greatly improved our understanding of disease pathogenesis and facilitated the discrimination of biologically and clinically distinct subgroups. Cytogenetic analysis and molecular screening for NPM1, FLT3 and CEBPA mutations have been widely adopted into the routine diagnostic work-up of AML, informing treatment decisions including the application of allogeneic SCT in first CR. The increasing number of molecular markers identified as a result of recent high throughput sequencing initiatives has presented a considerable challenge to establish the prognostic significance of particular constellations of mutations which may be relatively uncommon, demanding analysis of very large numbers of homogeneously treated patients. Nevertheless, it seems likely that these technologies will lead to the identification of new molecular markers with independent prognostic impact, which will improve prediction of an individual patient’s response to therapy. It is anticipated that further subgroups of patients who may benefit from particular (targeted) therapeutic approaches will be identified. In addition, technical improvements in flow cytometry with an increased number of available colours and the capacity to identify leukaemic stem cell populations, coupled with the development of an expanding range of RT-qPCR assays for leukaemia-specific molecular targets, make it highly plausible that longitudinal tracking of MRD can be applied in virtually every case of AML in the near future. These approaches could provide powerful tools to individually tailor a patient’s treatment throughout the entire course of the disease. This prospect will be extremely pertinent to the design of the next wave of large scale clinical trials which will need to establish the most informative molecular markers and determine whether the use of MRD monitoring to guide therapy is clinically useful, leading to meaningful improvements in patient survival.
DG gratefully acknowledges the National Institute for Health Research (NIHR) for support for molecular diagnostics and assessment of minimal residual disease in the UK NCRI AML17 trial. This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP- PG-0108-10093). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. In addition, DG gratefully acknowledges research funding from Leukaemia & Lymphoma Research of Great Britain, the Guy’s and St. Thomas’ Charity and the MRD Workpackage (WP12) of the European LeukemiaNet. AK acknowledges financial support from the Deutsche Krebshilfe. The authors also thank Dr Robert Hills for the data analyses summarised in Fig. 1.